From the FDA Drug Label
Adverse reactions that occurred in at least 5% of patients treated with bupropion HCl sustained-release (300 mg and 400 mg per day) and at a rate at least twice the placebo rate are listed below 300 mg/day of bupropion HCl sustained-release: anorexia, dry mouth, rash, sweating, tinnitus, and tremor.
The patient's symptoms of persistent fatigue and diaphoresis (excessive sweating) may be related to the use of bupropion, as sweating is listed as a common adverse reaction in the drug label 1. However, fatigue is not explicitly mentioned as an adverse reaction. Therefore, the cause of the patient's symptoms cannot be conclusively determined based on the provided information.
From the Research
The patient's persistent fatigue and diaphoresis are likely multifactorial, and I recommend a comprehensive approach to address potential underlying causes, including sleep apnea, hormonal changes, and medication side effects, as well as supplementation with vitamin D and consideration of cognitive behavioral therapy, as suggested by 2 and 3. Given her BMI of 42, obstructive sleep apnea is a strong possibility that could explain her profound fatigue and daytime sleepiness. The excessive sweating could indicate hormonal changes, an underlying inflammatory condition, or medication side effects.
- Additional laboratory tests to consider:
- Complete iron panel (including ferritin, iron, TIBC)
- Cortisol levels (morning cortisol or ACTH stimulation test)
- Inflammatory markers like rheumatoid factor
- Sleep study to evaluate for sleep apnea
- Comprehensive hormone panel including FSH, LH, and estradiol to assess for perimenopause
- The patient's low vitamin D level (23) should be addressed with supplementation, typically 2000-4000 IU daily, as this could be contributing to her fatigue, as suggested by 2.
- The normal thyroid function, A1c, and cholesterol are reassuring but don't explain her symptoms.
- Consideration of cognitive behavioral therapy may be beneficial in addressing chronic fatigue, as suggested by 2 and 3.
- The use of bupropion, as part of her current medication regimen, may have a role in managing her symptoms, as suggested by 4, but its effectiveness in this context is uncertain.
- The recent study on low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19, as reported in 5, may not be directly applicable to this patient's situation, but highlights the need for a comprehensive approach to addressing fatigue.